✦ LIBER ✦

Granulocyte—colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia

✍ Scribed by Heather G. Jørgensen; Mhairi Copland; Tessa L. Holyoake

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 58 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20742

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Granulocyte–colony-stimulating factor (f

Granulocyte–colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

✍ Alfonso Quintas-Cardama; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Maner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract ## BACKGROUND Imatinib mesylate administration has become standard treatment for patients with chronic myelogenous leukemia (CML). Although the safety profile of imatinib is favorable, Grade ≥ 3 neutropenia (according to the National Cancer Institute Common Toxicity Criteria) occurs in

Immune modulation of minimal residual di

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia : A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor

✍ Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garc 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB